“…[ 15 ] Consequently, it is highly demanded to replace the traditional‐doped Spiro‐OMeTAD by other dopant‐free HTMs for improved efficiency and stability of PSCs. [ 16,17–21 ] In this regard, there are a bunch of studies showing the possibility of molecular engineering on HTMs with very high performance. [ 14,22–24 ] Examples, such as the triazatruxene‐based KR321 (19.03%), [ 25 ] the spiro[fluorine‐9,9′‐xanthene]‐based N 2, N 2, N 7, N 7‐tetrakis(4‐methoxyphenyl)‐3′,6′‐bis(pyridin‐4‐ylmethoxy) spiro[fluorene‐9,9′‐xanthene]‐2,7‐diamine (19.5%), [ 26 ] the truxene‐based Trux‐OMeTAD (18.6%), [ 27 ] the quinolizino acridine incorporating FA‐CN (18.9%), [ 28 ] heteroacene‐based m ‐methoxy‐arylamine‐based di(1‐benzothieno)[3,2‐ b :2′,3′‐ d ]pyrrole (18.09%), [ 29 ] M7‐TFSI containing benzodithiophene and benzothiadiazole (17.4%), [ 30 ] triarylamine‐based TPAC3M (17.54%), [ 31 ] pyridine‐based D105 (17.40%) and D106 (18.24%), [ 32 ] cyclohexylidene‐derivative 4,4′‐cyclohexylidenebis[ N , N ‐bis(4‐methylphenyl) benzenamine] (p‐i‐n type; 18.80%), [ 33 ] and other types of small‐molecule HTMs, [ 23,24 ] all exhibit the PCE of >17% without the need for dopants/additives.…”